Soligenix 관리

관리 기준 확인 3/4

Soligenix CEO는 Christopher Schaber, Aug2006 에 임명되었습니다 의 임기는 18.25 년입니다. 총 연간 보상은 $ 700.49K, 74.2% 로 구성됩니다. 74.2% 급여 및 25.8% 보너스(회사 주식 및 옵션 포함). 는 $ 1.26K 가치에 해당하는 회사 주식의 0.015% 직접 소유합니다. 1.26K. 경영진과 이사회의 평균 재임 기간은 각각 10.4 년과 15.4 년입니다.

주요 정보

Christopher Schaber

최고 경영자

US$700.5k

총 보상

CEO 급여 비율	74.2%
CEO 임기	18.3yrs
CEO 소유권	0.02%
경영진 평균 재임 기간	10.4yrs
이사회 평균 재임 기간	15.4yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Christopher Schaber 의 보수는 Soligenix 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Sep 30 2024	n/a	n/a	-US$7m
Jun 30 2024	n/a	n/a	-US$7m
Mar 31 2024	n/a	n/a	-US$7m
Dec 31 2023	US$700k	US$519k	-US$6m
Sep 30 2023	n/a	n/a	-US$8m
Jun 30 2023	n/a	n/a	-US$10m
Mar 31 2023	n/a	n/a	-US$10m
Dec 31 2022	US$711k	US$499k	-US$14m
Sep 30 2022	n/a	n/a	-US$15m
Jun 30 2022	n/a	n/a	-US$15m
Mar 31 2022	n/a	n/a	-US$15m
Dec 31 2021	US$687k	US$485k	-US$13m
Sep 30 2021	n/a	n/a	-US$13m
Jun 30 2021	n/a	n/a	-US$12m
Mar 31 2021	n/a	n/a	-US$12m
Dec 31 2020	US$944k	US$475k	-US$18m
Sep 30 2020	n/a	n/a	-US$15m
Jun 30 2020	n/a	n/a	-US$16m
Mar 31 2020	n/a	n/a	-US$15m
Dec 31 2019	US$688k	US$466k	-US$9m
Sep 30 2019	n/a	n/a	-US$10m
Jun 30 2019	n/a	n/a	-US$9m
Mar 31 2019	n/a	n/a	-US$8m
Dec 31 2018	US$619k	US$453k	-US$9m
Sep 30 2018	n/a	n/a	-US$8m
Jun 30 2018	n/a	n/a	-US$7m
Mar 31 2018	n/a	n/a	-US$8m
Dec 31 2017	US$674k	US$444k	-US$7m

보상 대 시장: Christopher 의 총 보상 ($USD 700.49K )은 UK 시장( $USD 353.74K ).

보상과 수익: Christopher 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Christopher Schaber (58 yo)

18.3yrs

테뉴어

US$700,485

보상

Dr. Christopher J. Schaber, Ph D., has been the President and Chief Executive Officer at Soligenix, Inc. since August 30, 2006. Dr. Schaber has broad experience in the pharmaceutical and biotechnology indu...

리더십 팀

이름	위치	테뉴어	보상	소유권
Christopher Schaber	Chairman of the Board of Directors	18.3yrs	US$700.49k	0.015% $ 1.3k
Jonathan Guarino	Senior VP	5.2yrs	US$354.69k	0.0018% $ 152.6
Oreola Donini	Senior VP & Chief Scientific Officer	9.9yrs	US$387.59k	0% $ 0
Richard Straube	Senior VP & Chief Medical Officer	10.8yrs	US$249.94k	0.0014% $ 112.5

10.4yrs

평균 재임 기간

55yo

평균 연령

경험이 풍부한 관리: 0A6I 의 관리팀은 노련하고 경험 (평균 재직 기간 10.4 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Christopher Schaber	Chairman of the Board of Directors	18.3yrs	US$700.49k	0.015% $ 1.3k
Jerome Zeldis	Independent Director	13.4yrs	US$72.50k	0.0038% $ 319.3
Gregory Lapointe	Independent Director	15.7yrs	US$77.50k	0.0012% $ 103.4
Robert Rubin	Independent Director	15.1yrs	US$80.00k	0.00076% $ 63.4
Dorothy Mary Keefe	Member of Oral Mucositis Medical Advisory Board	no data	데이터 없음	데이터 없음
Jeffrey Hyams	Member of Pediatric Crohn's Disease Medical Advisory Board	no data	데이터 없음	데이터 없음
James Markowitz	Member of Pediatric Crohn's Disease Medical Advisory Board	no data	데이터 없음	데이터 없음
Joel Rosh	Member of Pediatric Crohn's Disease Medical Advisory Board	no data	데이터 없음	데이터 없음
Alain Rook	Member of Cutaneous T-Cell Lymphoma Medical Advisory Board	no data	데이터 없음	데이터 없음
Mark Schubert	Member of Oral Mucositis Medical Advisory Board	no data	데이터 없음	데이터 없음
Youn Kim	Member of Cutaneous T-Cell Lymphoma Medical Advisory Board	no data	데이터 없음	데이터 없음
Gary Wood	Member of Cutaneous T-Cell Lymphoma Medical Advisory Board	no data	데이터 없음	데이터 없음

15.4yrs

평균 재임 기간

69.5yo

평균 연령

경험이 풍부한 이사회: 0A6I 의 이사회는 노련하고 경험이 있습니다(평균 재직 기간 15.4 년).

Soligenix 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Soligenix, Inc. Announces Formation of European Medical Advisory Board for Cutaneous T-Cell Lymphoma

Soligenix, Inc., Annual General Meeting, May 23, 2024

Soligenix, Inc. Announces Formation of Behçet's Disease Medical Advisory Board

Insufficient new directors

Insufficient new directors

Insufficient new directors

Recent updates

Soligenix, Inc. Announces Formation of European Medical Advisory Board for Cutaneous T-Cell Lymphoma

Soligenix Initiates A Phase 2 Clinical Trial of SGX945 (Dusquetide) for the Treatment of Behcet's Disease

Third quarter 2024 earnings released: US$0.78 loss per share (vs US$2.56 loss in 3Q 2023)

Soligenix, Inc. Announces HyBryte Expanded Treatment Results to Be Presented at the European Organisation for Research and Treatment of Cancer Conference

Second quarter 2024 earnings released: US$1.31 loss per share (vs US$3.56 loss in 2Q 2023)

Soligenix, Inc. Announces Significant Progress in the Treatment of Cutaneous T-Cell Lymphoma with its Investigational Drug, HyBryte™

Soligenix, Inc. Announces an Interim Update on the Open-Label, Investigator-Initiated Study Evaluating Extended HyBryte Treatment for Up to 12 Months in Patients with Early-Stage Cutaneous T-Cell Lymphoma

Soligenix, Inc. Announces Positive Clinical Results from A Comparative Study Evaluating Hybryte™? Against Valchlor®? in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix, Inc. Announces Positive Clinical Results from HyBryte Compatibility Study in the Treatment of Cutaneous T-Cell Lymphoma

First quarter 2024 earnings released: US$0.18 loss per share (vs US$0.36 loss in 1Q 2023)

Soligenix, Inc., Annual General Meeting, May 23, 2024

Soligenix Extends Patent Protection for Its Filovirus Vaccine Platform to the United Kingdom and South Africa

Soligenix Announces Agreement on the Design of Second Confirmatory Placebo-Controlled Trial for Hybryte™ with the European Medicines Agency

Full year 2023 earnings released: US$0.79 loss per share (vs US$4.81 loss in FY 2022)

No longer forecast to breakeven

Soligenix, Inc. Announces Formation of Behçet's Disease Medical Advisory Board

FDA Grants Soligenix "Fast Track" Designation for Dusquetide in the Treatment of Oral Lesions of Behçet's Disease

Soligenix Announces Top-Line Results of the Phase 2A Study of Sgx302 (Synthetic Hypericin) in Patients with Mild-To-Moderate Psoriasis

Soligenix Announces Publication Demonstrating Complete Protection Against Filovirus Disease in Nonhuman Primate Models of Ebola and Marburg Viruses

Soligenix Receives Written Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Rule and Not Eligible for Second 180 Day Period

Insufficient new directors

Soligenix, Inc. Receives FDA IND Clearance for Phase 2 Clinical Trial of Dusquetide in Treatment of Aphthous Ulcers in Behçet's Disease

Third quarter 2023 earnings released: US$0.16 loss per share (vs US$1.15 loss in 3Q 2022)

Insufficient new directors

Soligenix, Inc. Announces HyBryte(TM) Expanded Treatment Trial in Cutaneous T-Cell Lymphoma Opens Enrollment

Insufficient new directors

Soligenix, Inc., Annual General Meeting, Sep 21, 2023

Soligenix Announces Expansion of SGX302 (Synthetic Hypericin) Phase 2a Study in Mild-to-Moderate Psoriasis

Timothy R. Coté Resigned as A Member of the Board of Directors of Soligenix, Inc

Soligenix Regains Compliance with the Shareholders’ Equity Requirement and in Compliance with All Other Applicable Requirements for Listing on Nasdaq

First quarter 2023 earnings released: US$0.36 loss per share (vs US$1.52 loss in 1Q 2022)

Soligenix, Inc. Announces Scheduling of Type A Meeting with the U.S. FDA to Review Proposed Study Design for a Second Phase 3 Study Evaluating HyBryte(TM) in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix Announces Positive Clinical Results from Compatibility Study of HyBryte in the Treatment of Cutaneous T-Cell Lymphoma

Soligenix, Inc. Announces Appointment of Timothy R. Coté, M.D. to Its Board of Directors

Insufficient new directors

No longer forecast to breakeven

No longer forecast to breakeven

Insufficient new directors

Soligenix, Inc. Receives Refusal to File Letter from U.S. FDA for Hybryte™ New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma

CEO 보상 분석

CEO

테뉴어

보상

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령